These results establish PAX2 epigenetic silencing as a specific, early, and highly recurring molecular driver event in EC, revealing what we believe to be a new paradigm for cancer-driving gene-level epigenetic alterations and creating directions for EC research. This evidence concerns the gene PAX2 and cancer.